Dr. Reddy’s Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

Shots:

• The approval is based on the clinical trial assessing Tosymra in patients with a migraine and demonstrated well tolerated and safe results
• Promius Pharma’s (subsidiary of Dr. Reddy) Tosymra (previously known as DFN-02) is a nasal spray developed using Intravail platform, targeted to treat adults with migraine with or without aura, to achieve equivalent blood level developed with the usage of 4-mg sumatriptan SC injection
• Intravail is a non-invasive drug delivery technology enabling delivery of multiple proteins, peptides and non-peptide drugs offering oral and buccal including dermal, and intranasal routes of drug administration

Click here  to read full press release/ article | Ref: Dr. Reddy | Image: Twitter